Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least 18 years old and are willing and capable of providing written-informed consent.~* Both men and non-pregnant women will be included.~* One group of 30 patients will have HIV.~* Another group of 30 patients will have drug-resistant TB (MDR or XDR).~* Remaining 60 patients will have drug-sensitive TB of which 30 will be assigned to placebo.~* TB infection documented prior to Study Entry by either the presence of TB rapid test or sputum smear positive for acid-fast bacilli (AFB).~* At least two independent tests are sought to confirm TB diagnosis.~* Agreement to participate in the study and to give a sample of blood for HIV testing.~Exclusion Criteria:~* Subjects who have already taken V5 in prior trial and those without baseline data.~* Those who met inclusion criteria can be retrospectively enrolled.~* Those who are re-treated and relapsed will be eligible as long as they are on the same drug regimen as the rest of patients.~* Pregnant or breast-feeding women are excluded.~* Subjects who have taken anti-retroviral drugs or immunomodulatory therapies within 2 months prior to Entry:~  * systemic corticosteroids~ * immune globulin (IV gamma globulin, IVIG)~ * interferons,~ * interleukins~ * pentoxifylline (Trental)~ * thalidomide~ * filgrastim (G-CSF)~ * sargramostim (GM-CSF)~ * dinitrochlorobenzene (DNCB)~ * thymosin alpha 1 (thymosin alpha)~ * thymopentin~ * inosiplex (Isoprinosine)~ * polyribonucleoside (Ampligen)~ * ditiocarb sodium (Imuthiol)~ * any locally available immune modulators~ * and any other therapeutic or preventive vaccine.~* Subjects requiring concurrent participation in another experimental research treatment study, or who received an experimental agent within four weeks prior to Study Entry.~* Medical conditions that in the opinion of the local investigator, may obscure the proper observation of the safety or activity of the study treatment; including any acute medical condition of unknown etiology or recent surgery prior to Entry.~* Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator, would interfere with adherence to the requirements of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Immunomodulator intervention (Type: ACTIVE_COMPARATOR): Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
- placebo (Type: PLACEBO_COMPARATOR): Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).